CHMP is reviewing avacopan, a drug authorized in the EU for treating adults with severe, active granulomatosis with polyangiitis or microscopic polyangiitis.

Compared with a standard dosing regimen, a reduced-dose glucocorticoid regimen is associated with an increased risk for disease progression, relapse, death, or kidney failure in antineutrophil ...

Nearly all (96%) patients with active AAV enrolled in the study achieved remission, with a median time to remission of 77 days. Early glucocorticoid withdrawal is feasible and was well tolerated in ...

In treatment-refractory EGPA, physicians should initiate additional investigations as soon as possible to identify the therapies best suited to prevent further clinical deterioration. A female child ...